Key points are not available for this paper at this time.
Last month, the U.S. Food and Drug Administration (FDA) announced that it plans to draft new guidelines for testing and approving the use of multidrug treatments for diseases. For cancer treatment, the need for this approach and its attendant guidelines are based on an advanced understanding of the disease that has emerged from 30 years of research. If we are to achieve breakthrough cancer therapies, current FDA regulations must change.
Arthur D. Levinson (Thu,) studied this question.